Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments

Novo Nordisk A/S
Posted on: 12 Sep 17

Lisbon, Portugal, 12 September 2017 - A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA 1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER). The analysis was presented today at the 53rd Annual Meeting of the European Association For The Study Of Diabetes. 1

"As a physician, helping patients with type 2 diabetes achieve glycaemic and weight loss targets can be challenging," said Dr Helena Rodbard, SUSTAIN 5 investigator and medical director at Endocrine and Metabolic Consultants, Rockville, Maryland. "The meaningful reductions demonstrated with semaglutide in both glucose and body weight are encouraging, as more treatment strategies are needed to help meet this challenge."

Significantly more people treated with once-weekly semaglutide achieved the clinically meaningful composite endpoint of > 1% HbA 1c reduction and >5% weight loss with 0.5 mg (25-35%) and 1.0 mg (38-56%) semaglutide vs. all comparators (2-13%; p<0.0001) in SUSTAIN 1-5. 1

In addition, more people achieved the composite endpoint with once-weekly semaglutide 1.0 mg compared with semaglutide 0.5 mg (p<0.0001 for SUSTAIN 2, 4 and 5; p=0.17 for SUSTAIN 1). 1

In this post-hoc analysis, semaglutide was well tolerated, with a safety profile similar to that of other glucagon-like peptide-1 receptor agonists. The most common adverse event with semaglutide was nausea. In SUSTAIN 1-4, severe or blood glucose confirmed symptomatic hypoglycaemia events were fewer or similar with once-weekly semaglutide vs. comparators. In SUSTAIN 5, on a background of basal insulin, more events were observed with once-weekly semaglutide than with placebo. 1


About semaglutide
Semaglutide is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake. 2-5 Once-weekly semaglutide is currently under review by seven regulatory agencies, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

About the SUSTAIN clinical trial programme
SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical trial programme for semaglutide, administered once weekly, that comprises seven phase 3a global clinical trials and a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes.

Further information
Media:    
Katrine Sperling+45 4442 6718 krsp@novonordisk.com
Åsa Josefsson+45 3079 7708 aajf@novonordisk.com
     
Investors :    
Peter Hugreffe Ankersen+45 3075 9085 phak@novonordisk.com
Hanna Ögren+45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen+45 3079 4461 armk@novonordisk.com
Christina Jensen+45 3079 3009 cnje@novonordisk.com
Kasper Veje (US)+1 609 235 8567 kpvj@novonordisk.com


References

 1.      Rodbard H, Bellary S, Hramiak I , et al. Responder analysis of subjects achieving HbA 1c  >1% and weight loss >5% across SUSTAIN 1-5 clinical trials. Poster 802. 53rd Annual Meeting of the European Association For The Study Of Diabetes (EASD), Lisbon, Portugal; 11-15 September 2017.
2.       Korsatko A, Brunner M, Sach-Friedl S , et al. Effect of once-weekly semaglutide on the counter-regulatory response to hypoglycaemia in subjects with type 2 diabetes. Abstract 764. 52 nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.
3.       Kapitza C, Dahl K, Jaconsen B , et al. The effects of once-weekly semaglutide on ß-cell function in subjects with type 2 diabetes. Abstract 754. 52 nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.
4.       Blundell J, Finlayson G, Axelsen MB , et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab . 2017; ePub ahad of print. DOI: 10.1111/dom.12932.
5.       Saad H, Hjersted J, Axelsen MB , et al. Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity. Canadian Journal of Diabetes . 2016; 40:S34-S35.

PR170912_EASD_semaglutide_UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire
HUG#2133076
GlobeNewswire
globenewswire.com

Last updated on: 13/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.